Tissue Diagnostics Market Set to Nearly Double by 2024-2030, Driven by Rising Cancer Burden and Digital Pathology Adoption

London, UK - November 26, 2025 | Strategic Revenue Insights Inc. - The global Tissue Diagnostics Market is poised for significant expansion over the next decade, with independent public domain estimates placing market value at approximately 8.63 billion in 2024 and projecting a rise to $14.03 billion by 2030.

Even under more conservative projections, market size is expected to grow from roughly $5.77 billion in 2025 to around $25.07 billion by 2033, representing a compound annual growth rate (CAGR) of about 12.58% during that period.

The anticipated rise in tissue diagnostics market size reflects mounting demand for accurate, early-stage disease detection particularly in oncology. As global cancer incidence increases and new cases rise each year, pathology and histopathology services become ever more critical.

In parallel, advances in diagnostic technologies including immunohistochemistry (IHC), in situ hybridization (ISH), and digital pathology are helping to speed up analysis, improve accuracy, and lower barriers for large-scale testing and biomarker identification.

A comprehensive assessment of this rapidly evolving market can be accessed through Strategic Revenue Insights at the link below, focused on Tissue Diagnostics:

https://www.strategicrevenueinsights.com/industry/tissue-diagnostic-market

Shifts in diagnostic workflows and a shortage of skilled pathologists worldwide further amplify demand. Digital slide scanning, whole slide imaging, and AI enabled image analysis tools are increasingly adopted, enabling remote pathology review, accelerating turnaround times, and standardizing diagnostics even in labs with limited personnel these technological and operational efficiencies are fostering broader uptake of tissue diagnostics across hospitals, diagnostic centers, research labs, and specialized cancer care facilities.

Regionally, North America remains the largest market, accounting for roughly 44-45% of global revenue in 2024. However, Asia Pacific is showing the fastest growth potential, driven by rising cancer incidence, expanding healthcare infrastructure, growing adoption of advanced diagnostics, and increasing public and private investment in healthcare capacity.

Market segmentation paints a clear picture of where demand is concentrated. In terms of technology, Immunohistochemistry (IHC) leads the market in revenue share, with a large portion of tissue diagnostics relying on IHC-based staining and analysis. At the same time, Digital Pathology & Workflow is the fastest growing segment laboratories worldwide are adopting digital pathology solutions for slide scanning, image storage, remote viewing, and AI assisted interpretation, driven by efficiency gains and demands for high throughput.

Browse the associated report:

https://www.strategicrevenueinsights.com/ja/industry/tissue-diagnostic-market

https://www.strategicrevenueinsights.com/kr/industry/tissue-diagnostic-market

https://www.strategicrevenueinsights.com/pt/industry/tissue-diagnostic-market

By application, cancer diagnostics especially breast cancer account for a substantial share of demand, reflecting both the high prevalence of the disease and the critical role of tissue histopathology in oncology. End users of tissue diagnostics include hospitals and cancer centers, diagnostic laboratories, research institutions, and specialized clinics with hospitals and large diagnostic centers leading revenue contribution due to integrated care models and demand for rapid pathology turnaround.

Looking ahead, the Tissue Diagnostics Market offers robust opportunity for expansion, innovation, and consolidation. Continued growth in global cancer incidence, rising demand for personalized medicine and biomarker guided therapies, and ongoing adoption of digital pathology and AI based image analysis are set to fuel demand. Labs and diagnostic centers investing in scalable workflow automation, slide digitization, and advanced staining/analysis platforms will be well-positioned to capture growing volume.

As healthcare access improves in emerging economies especially in Asia Pacific expansion is likely to be broad based rather than concentrated solely in developed markets.

For diagnostic providers, laboratory equipment and reagent manufacturers, healthcare investors, and hospital chains, the next decade offers both scale and strategic value. As diagnostics move upstream enabling early detection, precision treatment planning, and improved disease outcomes tissue diagnostics will remain central to oncology and pathology services globally.

Related Reports:

https://www.strategicrevenueinsights.com/industry/menopause-wellness-market

Media Contact

Company Name: Strategic Revenue Insights Inc.

Contact Person: Ashwani

Email: sales@strategicrevenueinsights.com

Phone: +44 7877 403352

Address: Suite 10, Capital House, 61 Amhurst Road, E8 1LL

City: London

Country: United Kingdom

Website: www.strategicrevenueinsights.com

Website: www.strategicpackaginginsights.com

About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd, empowers organizations worldwide with data-driven market intelligence. Headquartered in London, United Kingdom, the firm delivers syndicated research reports, tailored consulting solutions, and actionable insights that equip clients to make confident, future-focused strategic decisions. Its team of seasoned analysts continuously tracks markets, identifies emerging trends, and uncovers growth opportunities to support long-term client success. As part of SRI Consulting Group Ltd, Strategic Revenue Insights Inc. is committed to accuracy, clarity, and practical relevance, helping businesses optimize strategies and accelerate revenue growth.

This release was published on openPR.